- 13.01.2016
TR-Pharm (Turkey) and Crystal Genomics (Republic of Korea) with assistance of Taishi Group of Companies entered into a licensing agreement for commercialization of Crystal Genomics’ Acelex drug in Turkey and Middle East & North Africa region
TR-Pharm and Crystal Genomics announced jn January 12th, 2016 a Licensing and Supply Agreement for Crystal Genomics’ Acelex® (polmacoxib). The product, developed by Crystal Genomics, is a next generation COX-2 inhibitor that specifically targets affected joints. Acelex has been approved for the treatment of osteoarthritis in South Korea in February 2015. As a part of this agreement, TR-Pharm will have the rights to register, manufacture and commercialize the product in Turkey and MENA region.
Mehmet Göker, General Manager of TR-Pharm, said: “From the day of establishment of our company rheumatology has been one of the key areas of focus for TR-Pharm. Our target is to not only be with the patient and physician at every step but be a partner for health authorities across the region. We are very happy to be doing this with such an esteemed partner as Crystal Genomics”.
Chairman & CEO of Crystal Genomics, Dr.Joong Myung Cho said: “We are quite pleased with this partnership as it provides us with a great opportunity to penetrate the Turkish and MENA markets with TR-Pharm, a young pharmaceutical company with a clear vision to become a dominant player in the region with a competitive portfolio of novel therapeutics”.
TR-Pharm will commence immediately with technology transfer of the product to Turkey. This agreement will be an important component of TR-Pharm’s ongoing efforts to address patients and physician needs across the whole spectrum of inflammation with its in-licensed and pipeline products. As a result of this agreement, Crystal Genomics will also be extending the use of this novel therapy.
About TR-Pharm
TR Pharm is a pharma start-up focused on innovation with investments into R&D and a cutting edge biotechnological manufacturing capability with the aim of becoming a regional commercial player based out of Turkey.
TR Pharm focuses on the launch of new and innovative medicines starting from registration and accomplishment of clinical programs in all phases, as well as building a biotech manufacturing facility in Turkey for the supply of monoclonal antibodies to CIS and MENA region besides the local market. TR Pharm has a wide product portfolio, led by oncology, virology, inflammatory and rare diseases.
About Crystal Genomics
Crystal Genomics Inc. is a commercial stage biopharmaceutical company focused in the discovery and development of novel drugs in therapeutic areas, including inflammation, oncology, and infectious disease.